A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMGN SEC filings page.
Amgen Inc (AMGN) reported $38.9B in revenue over the twelve months to Sep 30, 2026, up 8.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Amgen’s 2025 rebound came with better margins and lower debt, but cash conversion weakened as investment and working capital absorbed more earnings.
Net income rose88.5% , yet operating cash flow fell13.3% in FY2025. With accounts receivable up41.1% and free cash flow down22.1% , the accounting rebound was not converting cleanly into cash.
Gross margin recovered to
Debt fell
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Amgen Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Amgen Inc scores 85/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Amgen Inc scores 73/100 on it among other operating companies.
Amgen Inc's net debt of $40.9B, being $50.0B of long-term debt less $9.1B of cash, came to 2.87 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Amgen Inc scores 21/100 among other operating companies.
Amgen Inc held $1.14 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.14. Liquidity ranks operating companies on that ratio, and Amgen Inc scores 27/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Amgen Inc scores 91/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Amgen Inc scores 74/100 on it among other operating companies.
Amgen Inc scores 2.23, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $250.1B against total liabilities of $81.9B. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Amgen Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Amgen Inc generates $1.29 in operating cash flow ($10.0B OCF vs $7.7B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Amgen Inc earns $3.30 in operating income for every $1 of interest expense ($9.1B vs $2.8B). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Amgen Inc generated $10.4B in revenue in Q3 2026. This represents an increase of 8.5% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.
Amgen Inc's EBITDA was $4.8B in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.1% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.
Amgen Inc reported $3.9B in net income in Q3 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is up 62.7%.
Amgen Inc earned $7.08 per diluted share (EPS) in Q3 2026. This represents an increase of 19.4% from the same quarter a year earlier. Against the prior quarter it is up 62.0%.
Cash & Balance Sheet
Amgen Inc generated $3.7B in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 4.7%.
Amgen Inc held $13.2B in cash against $51.6B in long-term debt as of Q3 2026.
Amgen Inc paid $2.52 per share in dividends in Q3 2026. This represents an increase of 5.9% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Amgen Inc's gross margin was 73.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 5.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Amgen Inc's operating margin was 35.8% in Q3 2026, reflecting core business profitability. This is up 9.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
Amgen Inc's net profit margin was 37.3% in Q3 2026, showing the share of revenue converted to profit. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.7 percentage points.
Amgen Inc's quarterly ROE was 26.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.6 percentage points.
Capital Allocation
Amgen Inc invested $2.1B in research and development in Q3 2026. This represents an increase of 11.1% from the same quarter a year earlier. Against the prior quarter it is up 13.0%.
Amgen Inc invested $587.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 34.6% from the same quarter a year earlier. Against the prior quarter it is up 14.4%.
Not reported for Q3 2026.
AMGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4B+8.5% | $10.1B+9.5% | $8.6B+5.8% | $9.9B+8.6% | $9.6B+12.4% | $9.2B+9.4% | $8.1B+9.4% | $9.1B+10.9% |
| Cost of Revenue | $2.8B-9.5% | $2.8B-6.6% | $2.7B-7.5% | $3.0B-4.4% | $3.1B-6.9% | $3.0B-7.0% | $3.0B-7.2% | $3.1B0.0% |
| Gross Profit | $7.6B+17.0% | $7.2B+17.4% | $5.9B+13.4% | $6.9B+15.3% | $6.5B+24.7% | $6.2B+19.7% | $5.2B+22.0% | $6.0B+17.5% |
| R&D Expenses | $2.1B+11.1% | $1.9B+7.1% | $1.7B+15.7% | $2.1B+24.2% | $1.9B+31.0% | $1.7B+20.5% | $1.5B+10.6% | $1.7B+12.4% |
| SG&A Expenses | $1.7B-2.3% | $1.7B+3.2% | $1.6B-5.0% | $2.0B+3.9% | $1.7B+5.8% | $1.7B-5.3% | $1.7B-6.7% | $1.9B-17.4% |
| Operating Income | $3.7B+46.9% | $3.5B+32.3% | $2.7B+126.3% | $2.7B+17.7% | $2.5B+23.4% | $2.7B+39.1% | $1.2B+18.9% | $2.3B+81.8% |
| EBITDA | $4.8B+26.1% | $4.6B+15.7% | $3.8B+47.4% | $3.9B+3.9% | $3.8B+11.3% | $4.0B+20.8% | $2.6B+7.3% | $3.7B+39.9% |
| Interest Expense | $653.0M-4.7% | $673.0M-3.0% | $657.0M-9.1% | $653.0M-12.6% | $685.0M-11.7% | $694.0M-14.1% | $723.0M-12.3% | $747.0M-9.0% |
| Income Tax | $822.0M+16.6% | $393.0M+189.0% | $265.0M+9.1% | $181.0M+16.8% | $705.0M+160.1% | $136.0M+183.3% | $243.0M+440.0% | $155.0M+82.4% |
| Net Income | $3.9B+20.1% | $2.4B+65.9% | $1.8B+5.1% | $1.3B+112.6% | $3.2B+13.6% | $1.4B+92.0% | $1.7Bn/m | $627.0M-18.3% |
| EPS (Basic) | $7.14+19.4% | $4.40+65.4% | $3.37+4.7% | $2.47+111.1% | $5.98+13.5% | $2.66+91.4% | $3.22n/m | $1.17-18.8% |
| EPS (Diluted) | $7.08+19.4% | $4.37+64.9% | $3.34+4.4% | $2.46+112.1% | $5.93+13.6% | $2.65+92.0% | $3.20n/m | $1.16-18.9% |
| Diluted Shares (Avg) | 546M+0.7% | 544M+0.6% | 544M+0.6% | N/A | 542M0.0% | 541M0.0% | 541M+0.9% | N/A |
AMGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $96.0B+6.6% | $95.6B+8.8% | $92.5B+3.5% | $90.6B-1.4% | $90.1B-0.8% | $87.9B-3.3% | $89.4B-3.9% | $91.8B-5.5% |
| Current Assets | $34.4B+23.2% | $35.0B+30.8% | $31.5B+16.9% | $29.1B+0.1% | $27.9B+4.2% | $26.7B-1.7% | $26.9B-3.9% | $29.0B-4.3% |
| Cash & Equivalents | $13.2B+39.7% | $14.0B+74.3% | $12.0B+36.6% | $9.1B-23.8% | $9.4B+4.8% | $8.0B-13.7% | $8.8B-9.3% | $12.0B+9.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $6.4B+0.7% | $6.2B-5.5% | $6.2B-8.1% | $6.2B-11.0% | $6.3B-13.8% | $6.6B-17.7% | $6.7B-22.9% | $7.0B-26.5% |
| Accounts Receivable | $10.4B+21.9% | $10.2B+17.5% | $9.1B+12.4% | $9.6B+41.1% | $8.5B+16.0% | $8.7B+25.5% | $8.1B+20.0% | $6.8B-6.7% |
| Goodwill | $18.7B-0.1% | $18.7B0.0% | $18.7B+0.2% | $18.7B+0.2% | $18.7B+0.1% | $18.7B+0.3% | $18.6B+0.4% | $18.6B0.0% |
| Total Liabilities | $81.7B+1.5% | $84.0B+4.3% | $83.3B+0.2% | $81.9B-4.7% | $80.5B-3.4% | $80.5B-5.3% | $83.2B-5.5% | $86.0B-5.5% |
| Current Liabilities | $23.2B+6.6% | $25.5B+24.5% | $25.0B+8.5% | $25.5B+10.3% | $21.8B+7.3% | $20.5B-4.8% | $23.0B+16.7% | $23.1B+25.6% |
| Non-Current Liabilities | $58.5B-0.5% | $58.4B-2.6% | $58.4B-3.0% | $56.4B-10.2% | $58.7B-6.8% | $60.0B-5.5% | $60.2B-11.9% | $62.9B-13.3% |
| Long-Term Debt | $51.6B-1.6% | $51.9B-3.5% | $51.9B-3.9% | $50.0B-11.6% | $52.4B-7.8% | $53.8B-5.9% | $54.0B-10.1% | $56.5B-10.5% |
| Total Equity | $14.4B+49.2% | $11.7B+57.4% | $9.2B+48.1% | $8.7B+47.3% | $9.6B+27.8% | $7.4B+25.4% | $6.2B+23.6% | $5.9B-5.7% |
| Retained Earnings | -$19.8Bn/m | -$22.3Bn/m | -$24.6Bn/m | -$25.1Bn/m | -$23.8Bn/m | -$25.7Bn/m | -$27.1Bn/m | -$27.6Bn/m |
Not reported in any period shown, so not listed: Long-Term Investments.
AMGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.2B-9.5% | $4.0B+75.5% | $2.2B+57.4% | $1.6B-66.4% | $4.7B+31.2% | $2.3B-7.3% | $1.4B+101.9% | $4.8B+786.8% |
| Depreciation & Amortization | $1.1B-14.2% | $1.1B-17.1% | $1.1B-19.5% | $1.1B-19.0% | $1.3B-6.4% | $1.3B-4.2% | $1.4B-0.9% | $1.4B+1.2% |
| Stock-Based Compensation | N/A | N/A | $75.0M-11.8% | N/A | N/A | N/A | $85.0M-17.5% | N/A |
| Capital Expenditures | $587.0M+34.6% | $513.0M+39.0% | $712.0M+73.2% | $642.0M+73.0% | $436.0M+69.6% | $369.0M+55.0% | $411.0M+78.7% | $371.0M+49.0% |
| Free Cash Flow | $3.7B-14.0% | $3.5B+82.6% | $1.5B+50.7% | $961.0M-78.2% | $4.2B+28.2% | $1.9B-14.0% | $980.0M+113.5% | $4.4B+1422.5% |
| Investing Cash Flow | -$649.0Mn/m | -$569.0Mn/m | -$716.0Mn/m | -$693.0Mn/m | -$414.0Mn/m | -$389.0Mn/m | -$447.0Mn/m | -$402.0Mn/m |
| Financing Cash Flow | -$4.4Bn/m | -$1.5Bn/m | $1.4Bn/m | -$1.2Bn/m | -$2.9Bn/m | -$2.7Bn/m | -$4.1Bn/m | -$1.4B-151.1% |
| Dividends Paid | $1.4B+6.3% | $1.4B+6.4% | $1.4B+6.2% | $1.3B+6.5% | $1.3B+6.0% | $1.3B+5.9% | $1.3B+5.9% | $1.2B+5.7% |
Not reported in any period shown, so not listed: Share Buybacks.
AMGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.1%+5.3pp | 72.0%+4.8pp | 68.2%+4.6pp | 69.8%+4.1pp | 67.8%+6.7pp | 67.2%+5.8pp | 63.6%+6.6pp | 65.8%+3.7pp |
| Operating Margin | 35.8%+9.4pp | 34.9%+6.0pp | 30.9%+16.5pp | 27.6%+2.1pp | 26.4%+2.4pp | 28.9%+6.2pp | 14.5%+1.2pp | 25.4%+9.9pp |
| Net Margin | 37.3%+3.6pp | 23.6%+8.0pp | 21.1%-0.1pp | 13.5%+6.6pp | 33.7%+0.4pp | 15.6%+6.7pp | 21.2%+22.7pp | 6.9%-2.5pp |
| Return on Equity | 26.9%-6.5pp | 20.3%+1.0pp | 19.8%-8.1pp | 15.4%+4.7pp | 33.4%-4.2pp | 19.3%+6.7pp | 27.9%+30.1pp | 10.7%-1.6pp |
| Return on Assets | 4.0%+0.4pp | 2.5%+0.9pp | 2.0%0.0pp | 1.5%+0.8pp | 3.6%+0.5pp | 1.6%+0.8pp | 1.9%+2.1pp | 0.7%-0.1pp |
| Current Ratio | 1.48+0.2x | 1.37+0.1x | 1.26+0.1x | 1.14-0.1x | 1.280.0x | 1.310.0x | 1.17-0.3x | 1.26-0.4x |
| Debt-to-Equity | 3.60-1.9x | 4.44-2.8x | 5.65-3.1x | 5.78-3.8x | 5.45-2.1x | 7.24-2.4x | 8.70-3.3x | 9.62-0.5x |
| Liabilities-to-Equity | 5.69-2.7x | 7.18-3.7x | 9.07-4.3x | 9.46-5.2x | 8.37-2.7x | 10.83-3.5x | 13.40-4.1x | 14.630.0x |
| Asset Turnover | 0.110.0x | 0.110.0x | 0.090.0x | 0.110.0x | 0.110.0x | 0.100.0x | 0.090.0x | 0.100.0x |
| FCF Margin | 35.3%-9.2pp | 34.7%+13.9pp | 17.1%+5.1pp | 9.7%-38.7pp | 44.5%+5.5pp | 20.8%-5.7pp | 12.0%+5.9pp | 48.4%+44.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $250.1B | 62/100 |
| AstraZeneca PLC AZN | FY2025 | $58.7B | $10.2B | 17.4% | $285.4B | 61/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $207.9B | 64/100 |
| Novartis AG NVS | FY2025 | $56.7B | $14.0B | 24.7% | $302.6B | 68/100 |
| Merck & Co., Inc. MRK | FY2025 | $65.0B | $18.3B | 28.1% | $356.1B | 64/100 |
| AbbVie Inc. ABBV | FY2025 | $61.2B | $4.2B | 6.9% | $520.8B | 57/100 |
Where Amgen Inc Ranks
Frequently Asked Questions
Amgen Inc (AMGN) reported $36.8B in total revenue for fiscal year 2025. This represents a 10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Amgen Inc (AMGN) revenue grew by 10.0% year-over-year, from $33.4B to $36.8B in fiscal year 2025.
Yes, Amgen Inc (AMGN) reported a net income of $9.4B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $7.7B, with a net profit margin of 21.0%.
Amgen Inc (AMGN) had EBITDA of $14.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Amgen Inc (AMGN) had $9.1B in cash and equivalents against $50.0B in long-term debt.
Amgen Inc (AMGN) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Amgen Inc (AMGN) had an operating margin of 24.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Amgen Inc (AMGN) had a net profit margin of 21.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Yes, Amgen Inc (AMGN) paid $9.66 per share in dividends during fiscal year 2025.
Amgen Inc (AMGN) has a return on equity of 89.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Amgen Inc (AMGN) generated $8.1B in free cash flow during fiscal year 2025. This represents a -22.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Amgen Inc (AMGN) generated $10.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Amgen Inc (AMGN) had $90.6B in total assets as of fiscal year 2025, including both current and long-term assets.
Amgen Inc (AMGN) invested $1.9B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Amgen Inc (AMGN) invested $7.3B in research and development during fiscal year 2025.
Amgen Inc (AMGN) had a current ratio of 1.14 as of fiscal year 2025, which is considered adequate.
Amgen Inc (AMGN) had a debt-to-equity ratio of 5.78 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Amgen Inc (AMGN) had a liabilities-to-equity ratio of 9.46 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Amgen Inc (AMGN) had a return on assets of 8.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Amgen Inc (AMGN) trades at 26.6x earnings, its market capitalization divided by $9.4B net income, trailing 12 months to September 30, 2026. The market capitalization is $250.1B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Amgen Inc (AMGN) trades at 6.4x sales, its market capitalization divided by $38.9B revenue, trailing 12 months to September 30, 2026. The market capitalization is $250.1B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Amgen Inc (AMGN) has an Altman Z-Score of 2.23, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Amgen Inc (AMGN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Amgen Inc (AMGN) has an earnings quality ratio of 1.29x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Amgen Inc (AMGN) has an interest coverage ratio of 3.30x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Amgen Inc (AMGN) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.